Uterine (endometrial) cancer affects the endometrium, which is the lining of the uterus. Many endometrial cancers are found in an early stage where they appear to be confined to the uterus. However, in some cases, cancer cells may spread to nearby lymph nodes and eventually to distant areas of the body. When uterine cancer has advanced to affect distant areas of the body, it may be called a stage 4 or advanced metastatic uterine cancer.
Metastatic uterine cancer symptoms
In its early stages, uterine cancer may not cause any noticeable symptoms. As this malignancy advances, however, symptoms may include:
- Vaginal bleeding between menstrual periods or after menopause
- Frequent or painful urination
- Pain during sexual intercourse
- Unexpected weight loss
- Persistent cramping in the pelvic area
- Other symptoms depending on the organ(s) affected
It is important to note that these symptoms do not necessarily mean you have uterine cancer. In fact, there are many other, more common conditions that can cause similar symptoms. Remember, early detection for uterine cancer is key for successful treatment. You should consult with a physician who can provide the necessary diagnostic tests to determine whether metastatic uterine cancer is the underlying cause.
Metastatic uterine cancer treatment
If you have been diagnosed with metastatic uterine cancer, the next step is to explore your treatment options. It is important to seek treatment from medical professionals who have a high level of experience treating advanced stages of uterine cancer. Moffitt Cancer Center is a high-volume cancer center that has treated many patients with uterine cancer. The multispecialty team within our Gynecologic Oncology Program are highly skilled and experienced at treating metastatic uterine cancer and will ensure you receive a treatment plan that is tailored to your specific needs. Treatment may involve a combination of surgery, chemotherapy or radiation therapy. Additionally, some patients may be eligible to participate in a clinical trial where they can gain access to the latest and most advanced treatment options before they may become widely available.
Medically reviewed by Robert Wenham, MD, Chair, Gynecologic Oncology Program